



May 9, 2024
Sysmex Corporation

Notice Regarding the Booking of a Loss on Valuation of Shares of Subsidiaries and Associates and a Provision for Loss on Guarantees (Non-Consolidated Financial Statements)

In its non-consolidated financial statements for the fiscal year ended March 31, 2024 (April 1, 2023 to March 31, 2024), Sysmex recorded a loss on valuation of shares of subsidiaries and associates and a provision for loss on guarantees as extraordinary losses. The details are as follows.

1. Details of extraordinary losses

As the real value of the shares it holds in Mediaroid Corporation has fallen, Sysmex has recorded a ¥12,955 million loss on valuation of shares of subsidiaries and associates and a ¥5,226 million provision for loss on guarantees as extraordinary losses in its non-consolidated financial statements for the fiscal year ended March 31, 2024.

These losses are due to the timing of the transition of Mediaroid Corporation's medical robotics business from the investment and development phase to the growth phase, which has resulted in upfront investments. As we believe that Mediaroid Corporation's medical robotics business will enter a growth phase, we will continue to invest in this business and Sysmex's medical robotics business.

2. Impact on consolidated operating performance

As the above-stated extraordinary loss was eliminated in consolidated accounting, the loss didn't affect Sysmex's consolidated operating performance for the fiscal year ended March 31, 2024.